We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Dishman Pharmaceuticals & Chemicals Ltd has said that the board of directors
of the company at its meeting has approved strategic acquisition of a UK-based
contract research company through its 100 percent wholly owned subsidiary (WOS)
company namely Dishman Europe.
Avid Bioservices, a wholly owned subsidiary of Peregrine Pharmaceuticals, (PPHM),
announced that it has signed a commercial manufacturing supply agreement with
Halozyme Therapeutics (HTI).
Adherex Technologies, a biopharmaceutical company with a broad portfolio of
oncology products under development, announced that the Drug Development Group
of the U.S. National Cancer Institute's (NCI) Division of Cancer Treatment and
Diagnosis has approved a Level III collaboration for the clinical development
of the company's lead biotechnology compound ADH-1, also known as Exherin, provided
additional preclinical studies be conducted.
Bradley Pharmaceuticals announced that purported
class action lawsuits have been filed in the United States District Court for
the District of New Jersey against the Company and, in some cases, certain of
its officers.
William Hubbard, the FDA's long-time associate commissioner for policy and planning,
has announced his retirement from the agency. Randall Lutter, of the FDA's Office
of Planning, will replace Hubbard.
Two senators have reintroduced bipartisan legislation that would allow states
to share information on residents' prescription drug use as way to crack down
on Rx drug abuse.
As part of its previously announced effort to divest
its brand pharmaceutical operations, Andrx has inked a deal to sell the rights
to its Fortamet and Altoprev products to First Horizon Pharmaceutical.
The FDA and the Justice Department have halted the distribution of GlaxoSmithKline's
(GSK) antidepressant Paxil CR and diabetes drug Avandamet because of ongoing
concerns about the manufacturing quality of the products.
TASC Pharmaceuticals Ltd., a leading manufacturer of active pharmaceutical ingredients
(API) and R&D service provider, said that it will merge with Glenmark Laboratories
Ltd., a niche formulations and biopharmaceuticals player, in a deal valued at
Rs12bn.